SlideShare a Scribd company logo
1 of 23
Joris Veltman (onderzoeker)
Personalized genomic medicine Joris Veltman j.veltman@antrg.umcn.nl www.genomicdisorders.nl
Het probleem; Ineffectieve medicijnen!
1953
Het humane genoom receptenboek voor leven 6 miljard bouwstenen 2001
NIJMEGEN INTERNATIONALE EXPERT ERFELIJKE ZIEKTEN VCAN CFH CHM USH2Aisob RPGRIP1 TECTA NDP EHMT1 EYS MYCN FXYD2 DFNB59  TSPAN12 ABCA4 CDH7 ESRRB P63 LARGE PDE6C SETBP1 RPGRIP1L OFD1 17Q21 LRTOMT TKS4 IKAROS MAOA SS18/SSX CEP290 SENP1/MESDC2 ZNF674 CNTNAP2 GRXCR1  TET2 CRB1 PRPS1 TBX4 RPGR TRPN L1/L2 LCA5 ROR2 EPCAM COL4A3
Complexiteit genonderzoek beperkt klinische impact! Fout in bouwstenen DNA ?        OF   	Fout in aantal chromosomen?
Genomics wordt spotgoedkoop! Kosten in kaart brengen 1 genoom
Genoomdiagnostiek in 2015  DNA ? Genoomsequentie < 1 uur < 500 euro
Nijmegen investeert in genoomsequencing Roche, GS FLX Titanium Since 11-2008 Life Technologies, SOLiD Since 9-2009
Van sequentie tot genoom:Veel puzzelwerk Miljoenen korte sequenties per individu Supercomputers en  Bioinformatica expertise! Totale genoomsequentie 1 individu
ACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAGTCGA ATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCACA CGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGA TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGCAAACGCACCG GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCCAACCAC GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGATCGA ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCG CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTACGATCG GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGAC GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCACT GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGCG ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGCT CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGA GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGGAC CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCATCG CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGA GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAATC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCCAC CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGGCAAAGGGGCCAA GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGAAACGCAC ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGTGC CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGAT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACG CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCAAGC CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATTAGCTA CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAACG GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACCC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACTCGA CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGAT TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCCAACT GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT
NRC 13 feb 2010
Personal genomics en impact op geneeskunde
Waarom reageren mensen verschillend op medicijnen?Oftewel: Hoe verschillend zijn ze nu echt? 5,999 miljard overeenkomsten 1 miljoen  verschillen
Wie ben ik en wat zijn mijn gezondheidsrisoco’s? Hoe zit het bij mij?
Een ander probleem; Recessieve ziekten Kans op dragerschap 1: 1000 Kans op dragerschap 1: 1000 Indien beide drager Dan kans van 1 op 4! Kans op ziekte 1: 4,000,000
Personalizedmedicine and the role of genomics PERSONALIZED GENOMIC MEDICINE DE TOEKOMST VAN DE GENEESKUNDE!
THANK YOU !
NEXT

More Related Content

What's hot

Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'Fundación Ramón Areces
 
Present and future of oncolytic virus therapies
Present and future of oncolytic virus therapiesPresent and future of oncolytic virus therapies
Present and future of oncolytic virus therapiesOncos Therapeutics
 
7 immunology-csbrp
7 immunology-csbrp7 immunology-csbrp
7 immunology-csbrpPrasad CSBR
 
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'Fundación Ramón Areces
 
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...Institut Pasteur de Madagascar
 
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell TransplantationCellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell Transplantationspa718
 
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry ReviseAnaliese Wenger
 
CCR5 Zincfinger
CCR5 ZincfingerCCR5 Zincfinger
CCR5 ZincfingerRyla Best
 
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...People with Multiple Sclerosis (Vic) Inc.
 
Jc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc AssaysJc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc Assaysnanog
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphismSimon Silvan
 
HPV vaccine (UID198612)
HPV vaccine (UID198612)HPV vaccine (UID198612)
HPV vaccine (UID198612)Freya Cardozo
 
ProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene OlingerProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene Olingeramandacturner
 
Sources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild TetraploidsSources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild TetraploidsBorlaug Global Rust Initiative
 

What's hot (19)

Qpcr
QpcrQpcr
Qpcr
 
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
 
Present and future of oncolytic virus therapies
Present and future of oncolytic virus therapiesPresent and future of oncolytic virus therapies
Present and future of oncolytic virus therapies
 
7 immunology-csbrp
7 immunology-csbrp7 immunology-csbrp
7 immunology-csbrp
 
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
 
PNAS 1992 FBH.PDF
PNAS 1992 FBH.PDFPNAS 1992 FBH.PDF
PNAS 1992 FBH.PDF
 
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
 
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell TransplantationCellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
 
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
 
2009 09 08 Wiltshire Ipit Seminar Slides
2009 09 08 Wiltshire Ipit Seminar Slides2009 09 08 Wiltshire Ipit Seminar Slides
2009 09 08 Wiltshire Ipit Seminar Slides
 
Seminar 08-10-2008 - wnt signaling system
Seminar 08-10-2008 - wnt signaling systemSeminar 08-10-2008 - wnt signaling system
Seminar 08-10-2008 - wnt signaling system
 
CCR5 Zincfinger
CCR5 ZincfingerCCR5 Zincfinger
CCR5 Zincfinger
 
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...
 
Jc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc AssaysJc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc Assays
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphism
 
HPV vaccine (UID198612)
HPV vaccine (UID198612)HPV vaccine (UID198612)
HPV vaccine (UID198612)
 
ProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene OlingerProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene Olinger
 
NK Immunodeficiencies
NK ImmunodeficienciesNK Immunodeficiencies
NK Immunodeficiencies
 
Sources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild TetraploidsSources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild Tetraploids
 

Similar to Joris Veltman

04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe FroguelAssociation LIR
 
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...Sherman Jia
 
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...Simon Gemble
 
Cancer regulators 2013
Cancer regulators 2013Cancer regulators 2013
Cancer regulators 2013Elsa von Licy
 
Paneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidosPaneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidosMauricio Lema
 
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias' Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias' Fundación Ramón Areces
 
Cancer drug targets 2013
Cancer drug targets 2013Cancer drug targets 2013
Cancer drug targets 2013Elsa von Licy
 
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases European School of Oncology
 
Tuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MDTuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MDNYU FACES
 
Rabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumRabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumEAFO1
 
sodapdf-converted.pptx
sodapdf-converted.pptxsodapdf-converted.pptx
sodapdf-converted.pptxEllyanaFarina1
 
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Fundación Ramón Areces
 
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Thermo Fisher Scientific
 
Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'Fundación Ramón Areces
 

Similar to Joris Veltman (20)

04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel
 
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
 
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
 
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
 
Cancer regulators 2013
Cancer regulators 2013Cancer regulators 2013
Cancer regulators 2013
 
Paneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidosPaneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidos
 
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias' Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
 
Apoptosis
ApoptosisApoptosis
Apoptosis
 
Cancer drug targets 2013
Cancer drug targets 2013Cancer drug targets 2013
Cancer drug targets 2013
 
Diaz-Arrastia, Ramon
Diaz-Arrastia, RamonDiaz-Arrastia, Ramon
Diaz-Arrastia, Ramon
 
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
 
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
 
Tuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MDTuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MD
 
Rabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumRabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_Forum
 
Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15
 
Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15
 
sodapdf-converted.pptx
sodapdf-converted.pptxsodapdf-converted.pptx
sodapdf-converted.pptx
 
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
 
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
 
Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'
 

More from UMC St Radboud (20)

Astrid Hartendorf
Astrid HartendorfAstrid Hartendorf
Astrid Hartendorf
 
Annet van Betuw
Annet van BetuwAnnet van Betuw
Annet van Betuw
 
Floortje Agema
Floortje AgemaFloortje Agema
Floortje Agema
 
Arjan Broers
Arjan BroersArjan Broers
Arjan Broers
 
Yvonne Engels en Jeroen Fokke
Yvonne Engels en Jeroen FokkeYvonne Engels en Jeroen Fokke
Yvonne Engels en Jeroen Fokke
 
Marjolein Roes
Marjolein RoesMarjolein Roes
Marjolein Roes
 
Erich Taubert
Erich TaubertErich Taubert
Erich Taubert
 
Geert Klein Breteler
Geert Klein BretelerGeert Klein Breteler
Geert Klein Breteler
 
Erik Jansen
Erik JansenErik Jansen
Erik Jansen
 
Irene Muller
Irene MullerIrene Muller
Irene Muller
 
Joia Stoutjesdijk
Joia StoutjesdijkJoia Stoutjesdijk
Joia Stoutjesdijk
 
Sietske van der Veldt
Sietske van der VeldtSietske van der Veldt
Sietske van der Veldt
 
Ellen van Bodegom
Ellen van BodegomEllen van Bodegom
Ellen van Bodegom
 
Saskia Timmer
Saskia TimmerSaskia Timmer
Saskia Timmer
 
Rob Speekenbrink
Rob SpeekenbrinkRob Speekenbrink
Rob Speekenbrink
 
Jaco van Duivenbode
Jaco van DuivenbodeJaco van Duivenbode
Jaco van Duivenbode
 
Salmaan Sana
Salmaan SanaSalmaan Sana
Salmaan Sana
 
Bart Timmers
Bart TimmersBart Timmers
Bart Timmers
 
Martijn vd Eijk
Martijn vd EijkMartijn vd Eijk
Martijn vd Eijk
 
Michiel Sedelaar
Michiel SedelaarMichiel Sedelaar
Michiel Sedelaar
 

Recently uploaded

Powerful Google developer tools for immediate impact! (2023-24 C)
Powerful Google developer tools for immediate impact! (2023-24 C)Powerful Google developer tools for immediate impact! (2023-24 C)
Powerful Google developer tools for immediate impact! (2023-24 C)wesley chun
 
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024The Digital Insurer
 
🐬 The future of MySQL is Postgres 🐘
🐬  The future of MySQL is Postgres   🐘🐬  The future of MySQL is Postgres   🐘
🐬 The future of MySQL is Postgres 🐘RTylerCroy
 
2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...Martijn de Jong
 
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...Miguel Araújo
 
What Are The Drone Anti-jamming Systems Technology?
What Are The Drone Anti-jamming Systems Technology?What Are The Drone Anti-jamming Systems Technology?
What Are The Drone Anti-jamming Systems Technology?Antenna Manufacturer Coco
 
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptxHampshireHUG
 
Strategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a FresherStrategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a FresherRemote DBA Services
 
Scaling API-first – The story of a global engineering organization
Scaling API-first – The story of a global engineering organizationScaling API-first – The story of a global engineering organization
Scaling API-first – The story of a global engineering organizationRadu Cotescu
 
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProduct Anonymous
 
The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024Rafal Los
 
Automating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps ScriptAutomating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps Scriptwesley chun
 
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time AutomationFrom Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time AutomationSafe Software
 
Handwritten Text Recognition for manuscripts and early printed texts
Handwritten Text Recognition for manuscripts and early printed textsHandwritten Text Recognition for manuscripts and early printed texts
Handwritten Text Recognition for manuscripts and early printed textsMaria Levchenko
 
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc
 
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...apidays
 
How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerHow to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerThousandEyes
 
Developing An App To Navigate The Roads of Brazil
Developing An App To Navigate The Roads of BrazilDeveloping An App To Navigate The Roads of Brazil
Developing An App To Navigate The Roads of BrazilV3cube
 
Real Time Object Detection Using Open CV
Real Time Object Detection Using Open CVReal Time Object Detection Using Open CV
Real Time Object Detection Using Open CVKhem
 
Boost PC performance: How more available memory can improve productivity
Boost PC performance: How more available memory can improve productivityBoost PC performance: How more available memory can improve productivity
Boost PC performance: How more available memory can improve productivityPrincipled Technologies
 

Recently uploaded (20)

Powerful Google developer tools for immediate impact! (2023-24 C)
Powerful Google developer tools for immediate impact! (2023-24 C)Powerful Google developer tools for immediate impact! (2023-24 C)
Powerful Google developer tools for immediate impact! (2023-24 C)
 
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
 
🐬 The future of MySQL is Postgres 🐘
🐬  The future of MySQL is Postgres   🐘🐬  The future of MySQL is Postgres   🐘
🐬 The future of MySQL is Postgres 🐘
 
2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...
 
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
 
What Are The Drone Anti-jamming Systems Technology?
What Are The Drone Anti-jamming Systems Technology?What Are The Drone Anti-jamming Systems Technology?
What Are The Drone Anti-jamming Systems Technology?
 
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
 
Strategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a FresherStrategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a Fresher
 
Scaling API-first – The story of a global engineering organization
Scaling API-first – The story of a global engineering organizationScaling API-first – The story of a global engineering organization
Scaling API-first – The story of a global engineering organization
 
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
 
The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024
 
Automating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps ScriptAutomating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps Script
 
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time AutomationFrom Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
 
Handwritten Text Recognition for manuscripts and early printed texts
Handwritten Text Recognition for manuscripts and early printed textsHandwritten Text Recognition for manuscripts and early printed texts
Handwritten Text Recognition for manuscripts and early printed texts
 
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
 
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
 
How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerHow to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected Worker
 
Developing An App To Navigate The Roads of Brazil
Developing An App To Navigate The Roads of BrazilDeveloping An App To Navigate The Roads of Brazil
Developing An App To Navigate The Roads of Brazil
 
Real Time Object Detection Using Open CV
Real Time Object Detection Using Open CVReal Time Object Detection Using Open CV
Real Time Object Detection Using Open CV
 
Boost PC performance: How more available memory can improve productivity
Boost PC performance: How more available memory can improve productivityBoost PC performance: How more available memory can improve productivity
Boost PC performance: How more available memory can improve productivity
 

Joris Veltman

  • 2. Personalized genomic medicine Joris Veltman j.veltman@antrg.umcn.nl www.genomicdisorders.nl
  • 5. Het humane genoom receptenboek voor leven 6 miljard bouwstenen 2001
  • 6.
  • 7. NIJMEGEN INTERNATIONALE EXPERT ERFELIJKE ZIEKTEN VCAN CFH CHM USH2Aisob RPGRIP1 TECTA NDP EHMT1 EYS MYCN FXYD2 DFNB59 TSPAN12 ABCA4 CDH7 ESRRB P63 LARGE PDE6C SETBP1 RPGRIP1L OFD1 17Q21 LRTOMT TKS4 IKAROS MAOA SS18/SSX CEP290 SENP1/MESDC2 ZNF674 CNTNAP2 GRXCR1 TET2 CRB1 PRPS1 TBX4 RPGR TRPN L1/L2 LCA5 ROR2 EPCAM COL4A3
  • 8. Complexiteit genonderzoek beperkt klinische impact! Fout in bouwstenen DNA ? OF Fout in aantal chromosomen?
  • 9. Genomics wordt spotgoedkoop! Kosten in kaart brengen 1 genoom
  • 10. Genoomdiagnostiek in 2015 DNA ? Genoomsequentie < 1 uur < 500 euro
  • 11. Nijmegen investeert in genoomsequencing Roche, GS FLX Titanium Since 11-2008 Life Technologies, SOLiD Since 9-2009
  • 12. Van sequentie tot genoom:Veel puzzelwerk Miljoenen korte sequenties per individu Supercomputers en Bioinformatica expertise! Totale genoomsequentie 1 individu
  • 13. ACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAGTCGA ATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCACA CGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGA TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGCAAACGCACCG GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCCAACCAC GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGATCGA ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCG CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTACGATCG GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGAC GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCACT GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGCG ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGCT CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGA GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGGAC CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCATCG CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGA GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAATC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCCAC CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGGCAAAGGGGCCAA GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGAAACGCAC ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGTGC CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGAT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACG CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCAAGC CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATTAGCTA CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAACG GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACCC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACTCGA CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGAT TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCCAACT GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT
  • 14. NRC 13 feb 2010
  • 15. Personal genomics en impact op geneeskunde
  • 16. Waarom reageren mensen verschillend op medicijnen?Oftewel: Hoe verschillend zijn ze nu echt? 5,999 miljard overeenkomsten 1 miljoen verschillen
  • 17.
  • 18. Wie ben ik en wat zijn mijn gezondheidsrisoco’s? Hoe zit het bij mij?
  • 19.
  • 20. Een ander probleem; Recessieve ziekten Kans op dragerschap 1: 1000 Kans op dragerschap 1: 1000 Indien beide drager Dan kans van 1 op 4! Kans op ziekte 1: 4,000,000
  • 21. Personalizedmedicine and the role of genomics PERSONALIZED GENOMIC MEDICINE DE TOEKOMST VAN DE GENEESKUNDE!
  • 23. NEXT